Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.
Place a direct purchase order on this report @ http://www.orbisresearch.com/contact/purchase/146208 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 18, 25, 71, 54, 6, 252, 85 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 66 and 20 molecules, respectively.Type 2 Diabetes.
Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Request a sample of Type 2 Diabetes – Pipeline Review, H2 2016
– The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Addex Therapeutics Ltd
Advinus Therapeutics Ltd.
Aegis Therapeutics, LLC
Alize Pharma SAS
AlphaMab Co., Ltd
Amarantus Bioscience Holdings, Inc.
Anchor Therapeutics, Inc.
Araim Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc.
Array BioPharma Inc.
Artery Therapeutics, Inc.
Astellas Pharma Inc.
AUS Bio Limited
Avaxia Biologics, Inc.
BioRestorative Therapies, Inc.
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Boston Therapeutics, Inc.
Braasch Biotech LLC
Bristol-Myers Squibb Company
C4X Discovery Holdings PLC
Cadila Pharmaceuticals Limited
Caldan Therapeutics Limited
Cardax Pharmaceuticals, Inc.
Carlina Technologies SAS
Carmot Therapeutics, Inc.
Catabasis Pharmaceuticals, Inc.
Celon Pharma Sp. z o.o.
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
Connexios Life Sciences Pvt. Ltd.
Corium International, Inc.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dance Biopharm Inc.
Debiopharm International SA
Diabetology (Products) Ltd
Diasome Pharmaceuticals, Inc.
Eisai Co., Ltd.
Elcelyx Therapeutics, Inc.
Eli Lilly and Company
Enzo Biochem, Inc.
Epichem Pty Ltd
Esperion Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Flamel Technologies S.A.
Foresee Pharmaceuticals, LLC
Generex Biotechnology Corporation
Genovate Biotechnology Co., LTD.
Glide Pharmaceutical Technologies Limited
Glucox Biotech AB
GW Pharmaceuticals Plc
Hadasit Medical Research Services & Development Ltd
Halozyme Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Heptares Therapeutics Limited
Hua Medicine Ltd.
Hyundai Pharmaceutical Co., Ltd.
Intarcia Therapeutics, Inc.
Integral Molecular, Inc.
IntelliCell BioSciences Inc.
Intercept Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
IPCA Laboratories Limited
Islet Sciences, Inc.
Japan Tobacco Inc.
Jeil Pharmaceutical Co., Ltd.
Jenrin Discovery, Inc.
JHL Biotech, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kareus Therapeutics, SA
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Lonestar Heart, Inc.
Longevity Biotech, Inc
Magnus Life Science
Medesis Pharma S.A.
Medestea Research & Production S.p.A.
Merck & Co., Inc.
Metabolic Solutions Development Company, LLC
MI.TO. Technology S.r.L.
MicroBiome Therapeutics LLC
MidaSol Therapeutics LP
Mitsubishi Tanabe Pharma Corporation
Neurimmune Holding AG
Neurocrine Biosciences, Inc.
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
NOD Pharmaceuticals, Inc.
Nordic Bioscience A/S
NovaTarg Therapeutics, Inc
Novo Nordisk A/S
Noxxon Pharma AG
OPKO Health, Inc.
Oramed Pharmaceuticals, Inc.
Orbis Biosciences, Inc.
Panacea Biotec Limited
Paras Biopharmaceuticals Finland Oy
PhaseBio Pharmaceuticals, Inc.
Pivot Pharmaceuticals Inc
Progen Pharmaceuticals Limited
Prometheon Pharma, LLC
ProMetic Life Sciences Inc.
Prothena Corporation Plc
Purzer Pharmaceutical Co., Ltd.
Reata Pharmaceuticals, Inc.
Red Glead Discovery AB
Rhizen Pharmaceuticals S.A.
Rhythm Pharmaceuticals, Inc.
Sanwa Kagaku Kenkyusho Co., Ltd.
SATT Conectus Alsace SAS
SBI Pharmaceuticals Co., Ltd.
Seres Therapeutics, Inc.
Sevion Therapeutics, Inc.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Pharmaceutical Co., Ltd.
Shantani Proteome Analytics Pvt. Ltd.
Shionogi & Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Sirona Biochem Corp
SJT Molecular Research, S.L.
SK Chemicals Co., Ltd.
Sprint Bioscience AB
Starpharma Holdings Limited
Stelic Institute & Co., Inc.
Strongbridge Biopharma plc
Sumitomo Dainippon Pharma Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
Takeda Pharmaceutical Company Limited
Teijin Pharma Limited
Therapix Biosciences Ltd
Thermalin Diabetes, LLC
Thetis Pharmaceuticals LLC
Toray Industries, Inc.
Torrent Pharmaceuticals Limited
Transgene Biotek Limited
TWi Pharmaceuticals, Inc.
Uni-Bio Science Group Ltd.
Valeant Pharmaceuticals International, Inc.
Vicore Pharma AB
Viking Therapeutics, Inc.
vTv Therapeutics LLC
XBiotech USA, Inc.
Xenetic Biosciences (UK) Limited
Xizang Haisco Pharmaceutical Group Co., Ltd.
Yungjin Pharm. Co., Ltd.
Zealand Pharma A/S
Zensun (Shanghai) Sci & Tech Co., Ltd.
Zydus Cadila Healthcare Limited
Browse the complete report @ http://www.orbisresearch.com/reports/index/type-2-diabetes-pipeline-review-h2-2016 .
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com